Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
复制标题
DOI：
10.1136/annrheumdis-2014-206439
复制
发表时间：
2016-01-01
影响因子：
27.4
通讯作者：
Rech, Juergen
中科院分区：
文献类型：
--
作者：
Haschka, Judith;Englbrecht, Matthias;Rech, Juergen
目的 在一项前瞻性随机对照试验中，前瞻性分析持续缓解的类风湿关节炎 (RA) 患者，无论是继续、逐渐减少或停止使用缓解病情的抗风湿药物 (DMARD)，疾病复发的风险。方法 持续缓解的类风湿关节炎患者减少治疗是一项多中心、随机对照、平行组 3 期试验，评估逐渐减少和停止所有常规和/或生物 DMARD 患者的效果。 RA 处于稳定缓解状态。患者（疾病活动评分 28 (DAS28)
Objective To prospectively analyse the risk for disease relapses in patients with rheumatoid arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-modifying antirheumatic drugs (DMARDs) in a prospective randomised controlled trial.Methods Reduction of Therapy in patients with Rheumatoid arthritis in Ongoing remission is a multicentre, randomised controlled, parallel-group phase 3 trial evaluating the effects of tapering and stopping all conventional and/or biological DMARDs in patients with RA in stable remission. Patients (disease activity score 28 (DAS28)